ストックスクリーナーアプリを入手
8.865
1.90%
0.165
前日終値:
$8.70
開ける：
$8.86
24時間の取引高:
125.60K
Relative Volume:
1.10
時価総額：
$228.77M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-6.2872
EPS:
-1.41
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
+3.99%
1か月 パフォーマンス:
-6.59%
6か月 パフォーマンス:
+31.14%
1年 パフォーマンス:
+31.14%
1日の値動き範囲:
$8.78
$9.30
1週間の範囲:
$8.25
$10.19
52週間の値動き範囲:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
8.865 | 228.77M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Is Nuvectis Pharma Inc (NASDAQ: NVCT) A Good Pick For New Investors Now? - Stocksregister
Nuvectis Pharma prices 2.7M shares at $5.00 in underwritten public offering - MSN
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$36m last week; individual investors who hold 48% profited and so did insiders - simplywall.st
When the Price of (NVCT) Talks, People Listen - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Maxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Maxim Initiates Nuvectis Pharma at Buy With $17 Price Target - MarketScreener
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference - MarketScreener
(NVCT) Investment Analysis - news.stocktradersdaily.com
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
New Cancer Treatment Breakthrough: NXP900 Data Showcase at Major AACR Conference - Stock Titan
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Large Decline in Short Interest - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Now Covered by Analysts at Laidlaw - Defense World
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - Nasdaq
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target By Investing.com - Investing.com Canada
Nuvectis Pharma initiated with a Buy at Laidlaw - TipRanks
Laidlaw starts Nuvectis Pharma stock with Buy, $19 target - Investing.com
(NVCT) Long Term Investment Analysis - news.stocktradersdaily.com
Nuvectis Pharma to Participate in the 37th Annual Roth Conference - GlobeNewswire
Nuvectis Pharma CEO Fireside Chat: Key Oncology Pipeline Updates Coming at Roth Conference - StockTitan
Oppenheimer & Co. Inc. Takes Position in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis announces new publication of research study on NXP900, osimertinib - TipRanks
Nuvectis reports promising cancer treatment results - Investing.com
Nuvectis reports promising cancer treatment results By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces a New Publication of a Research - GlobeNewswire
Cleveland Clinic Study Confirms: Nuvectis Drug Makes Standard Lung Cancer Treatment More Effective - StockTitan
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC - Yahoo Finance
Roth Capital Forecasts Reduced Earnings for Nuvectis Pharma - Armenian Reporter
HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings - Defense World
Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
Nuvectis Pharma (NASDAQ:NVCT) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Price Target Lowered to $11.00 at HC Wainwright - MarketBeat
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst - MarketBeat
FY2028 EPS Estimates for Nuvectis Pharma Reduced by Analyst - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Progress - TipRanks
Market News Alert: Nuvectis Pharma Receives $18 Price Target and Buy Rating from Lucid Capital Markets - Marketscreener.com
HC Wainwright Lowers Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00 - Defense World
Nuvectis Pharma Reports 2024 Financial Results and Updates on Oncology Pipeline - Defense World
Nuvectis Pharma initiated with a Buy at Lucid Capital - TipRanks
Optimistic Buy Rating for Nuvectis Pharma Driven by Promising Oncology Pipeline and Strong Financial Position - TipRanks
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright - TipRanks
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year - TipRanks
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights - The Manila Times
How Nuvectis Pharma Cut Losses by $3.3M While Pushing Forward Two Cancer Drug Candidates - StockTitan
Insiders Rewarded With US$915k Addition To Investment As Nuvectis Pharma Stock Hits US$185m - Simply Wall St
Nuvectis Pharma announces pricing of $13.5M public offering - MSN
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock - MarketBeat
Nuvectis pharma investor acquires $1.2 million in stock - MSN
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):